Structure’s Oral Weight Loss Drug Data Underperforms A Big Rival

The company is advancing a Phase II candidate in the closely watched and competitive category of oral GLP-1 receptor agonists for diabetes and weight loss.

tape measure — Investors weren't sure Structure's Phase II data measures up to Lilly's • Source: Shutterstock

A Phase IIa clinical trial testing Structure Therapeutics, Inc.’s oral GLP-1 receptor agonist GSBR-1290 in patients with type 2 diabetes met the primary safety and tolerability endpoints and showed a statistically significant reduction in hemoglobin A1c and weight at week 12, but investors were hoping to see stronger efficacy results.

Key Takeaways

A Phase IIa clinical trial testing Structure Therapeutics Inc.’s oral GLP-1 receptor agonist GSBR-1290 was positive for safety and efficacy.
Weight loss was a secondary endpoint and showed lower trends than a Phase II trial run by Lilly for orforglipron

Structure’s stock price tumbled 46% after the company announced the news, opening 18 December at $31.90, despite positive results

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.